[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neurological-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neurological-disorder":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,48,76,101,143,174,204,226,255,281,307],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":4,"leadSponsor":44,"locationsCount":47},"100192257","studying-childhood-onset-behavioral-psychiatric-and-developmental-disorders-100192257",false,"NCT01778504","Studying Childhood-onset Behavioral, Psychiatric, and Developmental Disorders","Diagnosis of Childhood-onset Behavioral Disorders, Neuropsychiatric Disorders and Neurodevelopmental Disorders","* INCLUSION CRITERIA:\n\nParticipants will be eligible if they:\n\n1. Are aged birth to 99 years\n2. Have a diagnosed or undiagnosed neuropsychiatric disorder, neurodevelopmental disability or abnormal behaviors.\n3. Have the ability to understand and sign an informed consent on behalf of themselves or their minor children, or have a legal guardian (or designated DPA).\n4. Are under the care of a primary physician.\n\nEXCLUSION CRITERIA:\n\nParticipants will not be eligible if they:\n\n* Are unwilling or unable to be evaluated and followed as clinically indicated. Examples might include children with severe behavioral problems who refuse physical examination.\n* The participant does not have a primary healthcare provider.",true,"ALL","1 Day","99 Years",{"count":21,"type":22},1000,"ESTIMATED","OBSERVATIONAL","Background:\n\n\\- Many psychiatric, behavioral, and developmental disorders are genetic. This means that they tend to run in families. Some begin in childhood, while others do not appear until adulthood. Researchers want to look at people of all ages who have these disorders that started in childhood. They will also look at relatives of people with these disorders. This information will allow doctors to learn more about childhood behavioral problems and how they are inherited. It may also help doctors treat those disorders.\n\nObjectives:\n\n\\- To study the onset and treatment of childhood behavioral, psychiatric, and developmental disorders.\n\nEligibility:\n\n* Individuals of any age who have a psychiatric, autism spectrum, or developmental disorder, or other behavioral problems.\n* Family members of individuals with the above disorders. This group may include parents, grandparents, siblings, aunts\u002Funcles, cousins, and children.\n\nDesign:\n\n\\- Participants will be screened with a medical history and physical exam. They may have a psychiatric history with tests of thinking, judgment, and behavior. Brain imaging scans may be performed to look at brain function.",[26,27,28,29],"Neuropsychiatric Disorder","Neurological Disorder","Neurodevelopmental Disorder","Sleep",[31,32,33,34,35,36],"Natural History Study","Mental Illness","Autism","Developmental Delay","Genetic Disorder","Natural History","RECRUITING","2026-06-23",{"date":40,"type":41},"2026-06-24","ACTUAL",{"date":43,"type":41},"2012-12-27",{"name":45,"class":46},"National Institute of Mental Health (NIMH)","NIH",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":52,"conditions":60,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":75},"100634721","independence-through-endovascular-neuroprosthetic-technology-intent-an-early-feasibility-study-100634721","NCT07543367","INdependence Through Endovascular Neuroprosthetic Technology (INTENT): an Early Feasibility Study","Inclusion Criteria:\n\n* Able to provide informed consent to participate in the study.\n* Diagnosis of ALS, with bilateral upper-limb paresis.\n* ALS must be refractory to treatment and have been present for a minimum of six months.\n* Aged 22 years or older.\n* Life expectancy greater than 12 months post-implantation.\n* Preserved precentral gyrus assessed using CT.\n* Suitable vascular anatomy assessed using CT venography.\n* Suitable anatomy for subcutaneous pocket creation.\n* Able to undergo anesthesia.\n* Willing and able to comply with all investigational requirements, including clinical testing visits and training visits in the home.\n* Caregiver(s) willing and able to facilitate study visits, including visits to the study site and in the home, and BCI use outside of study visits (e.g., device charging).\n* Patient and caregiver fluent in English.\n* Suitable home environment for BCI training.\n\nExclusion Criteria:\n\n* Active infection or unexplained fever in the 48 hours prior to informed consent.\n* Major psychiatric disorder that may adversely impact the participant's safety or study compliance, including severe depression, psychotic features, personality disorder, severe emotional lability, or substance abuse.\n* Diagnosis of ALS-FTD or another dementia.\n* Active implanted device (e.g., deep brain stimulator, cardiac defibrillator, pacemaker, vagal nerve stimulator, spinal cord stimulator, diaphragmatic pacer, etc.).\n* Known allergy to patient-contacting materials included in the implanted device.\n* Contraindication to angiographic imaging or iodine contrast media.\n* History of central venous sinus thrombosis.\n* Recent history of new venous thromboembolic event (in the 6 months prior to implant), recurrent history of venous thromboembolic disease, or hypercoagulable state.\n* Contraindication to antithrombotic therapy.\n* Participant is at substantially increased risk of infection, including immunocompromised status, recurrent or chronic infection, or poorly controlled diabetes mellitus.\n* Significant risk of non-healing of the subcutaneous pocket incision, including history of chronic non-healing surgical wounds or poorly controlled diabetes mellitus.\n* Pregnant or breast feeding.\n* Patients who are currently enrolled in any other clinical trial that would confound interpretation of safety or effectiveness data or may interfere with the ability to meet study requirements.\n* Any other disease or disorder that could significantly affect participation in the study. Examples may include corrected vision insufficient for viewing computer screens or hearing insufficient for following verbal instructions, which might impact the participant's ability to participate in BCI training and testing.","22 Years",{"count":56,"type":22},10,"INTERVENTIONAL",[59],"NA",[27,61,62,63,64],"ALS (Amyotrophic Lateral Sclerosis)","Motor Neuron Disease","ALS - Amyotrophic Lateral Sclerosis","ALS","2026-05-07",{"date":67,"type":41},"2026-05-11",{"date":69,"type":22},"2026-04",{"date":71,"type":22},"2029-12",{"name":73,"class":74},"Synchron, Inc.","INDUSTRY",5,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":57,"phases":85,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":47},"100565547","healing-tiny-minds-rural-recovery-through-virtual-and-lived-experience-care-100565547","NCT06643598","Healing Tiny Minds: Rural Recovery Through Virtual and Lived Experience Care","Inclusion Criteria:\n\n1. IPNH-NDCP patients, including:\n\n   * Term-born children diagnosed during the neonatal period with hypoxic-ischemic encephalopathy, or\n   * premature children (born at less than 28 weeks gestational age).\n2. Parent or legal guardian will also be enrolled as a participant\n3. Parents must be English-speaking (able to provide consent and complete questionnaires).\n\nExclusion Criteria:\n\n1. Not suitable for study participation due to other reasons at the discretion of the investigator.\n2. Infants with chromosomal abnormalities, genetic syndromes (for example, such as Down Syndrome or Trisomy18) and major congenital malformations will be excluded.\n3. Infants with vision impairment will also be excluded from the study, as our study procedures do require intact vision to be able to complete.\n4. For parents or legal guardians, there are no exclusion criteria.","5 Years",{"count":84,"type":22},225,[59],"The goal of this behavioral-interventional study is to learn if the Abecedarian Approach implemented virtually for children ages 0-5 with a history of Hypoxic Ischaemic Encephalopathy (HIE) and\u002For premature birth produces the same effects as when administered at in-person facilities.",[88,89,90,27],"Hypoxic Ischaemic Encephalopathy (HIE)","Premature Birth","Cerebral Palsy","2026-03-24",{"date":93,"type":41},"2026-03-27",{"date":95,"type":41},"2025-06-03",{"date":97,"type":22},"2030-03",{"name":99,"class":100},"University of Wisconsin, Madison","OTHER",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":17,"minAge":108,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":57,"phases":111,"briefSummary":112,"conditions":113,"keywords":125,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":47},"100609711","trans-auricular-stimulation-for-postoperative-inflammation-in-spine-surgery-100609711","NCT07218133","Trans-Auricular Stimulation for Postoperative Inflammation in Spine Surgery","TAPIS","Inclusion Criteria:\n\n* Long-segment spinal fusions (defined as constructs spanning at least L2-pelvis for thoracolumbar fusions or C2-T2 for cervical fusions)\n* Ability to undergo a reliable neurologic examination and pain assessments\n\nExclusion Criteria:\n\n* Patients \\\u003C18 years of age\n* Shorter-segment spinal fusions than those described above\n* Undergoing current active cancer therapy\n* Undergoing treatment with immunosuppressive drugs\n* Additional spinal surgery within past 6 months\n* Sustained bradycardia or presence of pacemaker\n* History of substance abuse","18 Years",{"count":110,"type":22},50,[59],"This study is a randomized controlled trial that will evaluate the effect of non-invasive auricular vagal nerve stimulation on inflammatory markers, glycemic control, postoperative pain, and inflammation-related clinical outcomes after long-segment spinal fusion surgeries when compared to current accepted management.",[114,115,116,117,118,119,27,120,121,122,123,124],"Spinal Fusion","Hyperglycemia","Postoperative Pain Management","Postoperative Care","Spine Disease","Neurologic Deficits","Inflammation","Spine Condition","Spinal (Fusion) Surgery","Cytokine Levels","Spine Fusion",[126,127,128,129,130,131,132,133],"spinal fusion","postoperative pain","glycemic control","inflammation","vagal nerve stimulation","postoperative complications","cytokine","spine surgery","2026-02-17",{"date":136,"type":41},"2026-02-20",{"date":138,"type":41},"2025-10-08",{"date":140,"type":22},"2026-12",{"name":142,"class":100},"Alexander T. Yahanda",{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":149,"eligibilityCriteria":150,"healthyVolunteers":11,"sex":17,"minAge":108,"maxAge":4,"enrollmentInfo":151,"targetDuration":4,"studyType":57,"phases":153,"briefSummary":155,"conditions":156,"keywords":163,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":171,"locationsCount":173},"100579076","phase-3-prophylaxis-against-early-ventilator-associated-infections-in-acute-brain-injury-100579076","NCT06819592","PRophylaxis Against Early VENTilator-associated Infections in Acute Brain Injury","PRophylaxis Against Early VENTilator-associated Infections to Reduce Mortality in Mechanically Ventilated Intensive Care Unit (ICU) Patients With Acute Brain Injuries: a Phase 3 Randomised, Double Blind, Parallel Group, Placebo-controlled Two-side Superiority Trial","PREVENT-NEURO","Inclusion Criteria:\n\n1. ≥ 18 years of age\n2. Receiving invasive mechanical ventilation\n3. The requirement for mechanical ventilation is because of an acute brain injury due to intracranial haemorrhage, ischaemic stroke, cerebral venous sinus thrombosis, subarachnoid haemorrhage, suspected hypoxic ischaemic encephalopathy post cardiac arrest, or traumatic brain injury.\n4. Admitted to an ICU or is anticipated to be admitted to an ICU\n\nExclusion Criteria:\n\n1. Endotracheal intubation was more than 12 hours ago\n2. Hospital admission was more than 72 hours ago\n3. Anticipated inability to deliver trial intervention within 90 minutes of randomisation\n4. Documented use of antibiotic therapy in the week prior to hospitalisation\n5. Currently receiving antibiotic therapy, or intention to prescribe antibiotic therapy, excluding cephazolin for peri-operative prophylaxis\n6. Any contraindication to receiving ceftriaxone\n7. Known or suspected pregnancy\n8. Death within 90 days is deemed inevitable due to the current illness or intercurrent medical conditions\n9. Previously enrolled in the PREVENT-NEURO trial.",{"count":152,"type":22},3300,[154],"PHASE3","This research is about whether treatment with a commonly used antibiotic can prevent infections in airway and lungs and improves the chance of surviving, if it is given soon after patients commence mechanical ventilation when they have been admitted to hospital with an acute severe brain injury.\n\nAn acute severe brain injury can occur as a result of a stroke, a traumatic injury or due to lack of oxygen to the brain that happens as a result of a cardiac arrest.\n\nPatients who are unconscious after an acute severe brain injury often need assistance to breath adequately, and this assistance is given by a breathing tube, connected to a mechanical ventilator. This treatment is an emergency medical treatment. The breathing tube is inserted into the patients' airway by either their mouth or neck. For patients who need assistance with their breathing from a mechanical ventilator, infections in the airways and lungs, known as pneumonia, are a common complication. Everyone naturally has bacteria in their mouth, esophagus and stomach. Clinicians think that during the process of inserting the breathing tube, small amounts of these bacteria can be introduced into the airways and lung when people are unconscious following an acute severe brain injury, or during the process of placing the breathing tube into the airways. These bacteria are now in a place they aren't meant to be and can cause an infections in the airways and lungs known as pneumonia.\n\nThe purpose of this research is to see if giving one dose of a common antibiotic can prevent patients developing pneumonia, which is associated with having a breathing tube inserted and being on a ventilator, improving the chance of recovery following the acute severe brain injury and ultimately improving the chance of surviving.\n\nWhen patients have a known infection, current guidelines are to treat them with antibiotics. Antibiotics work to kill the bacteria causing the infection. When a patient has an infection in their lungs, they often need to stay on the mechanical ventilator for longer. While current practice is to give patients with a proven infection in their airways and lungs (pneumonia) antibiotics, it is unknown if giving an antibiotic to patients to prevent these infections before they show signs of pneumonia may lead to better outcomes.",[157,158,159,27,160,161,162],"All-cause Mortality","Quality of Life","Disability, Intellectual","Acute Brain Injury","Ventilation, Mechanical","Intensive Care Medicine",[160,164],"Mechanical Ventilation","2026-02-16",{"date":167,"type":41},"2026-02-19",{"date":169,"type":41},"2025-10-30",{"date":71,"type":22},{"name":172,"class":100},"The George Institute",9,{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":180,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":17,"minAge":108,"maxAge":4,"enrollmentInfo":182,"targetDuration":4,"studyType":57,"phases":184,"briefSummary":185,"conditions":186,"keywords":188,"overallStatus":194,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":4},"100590236","the-mechatronic-remote-physiotherapy-system-mrps-in-remote-stroke-rehabilitation-100590236","NCT06964789","The Mechatronic Remote Physiotherapy System (MRPS) in Remote Stroke Rehabilitation","The Mechatronic Remote Physiotherapy System (MRPS) in Remote Stroke Rehabilitation: A Pilot Controlled Trial for 'Early Supported Discharge'","MRPS","Inclusion Criteria:\n\n* A clinical diagnosis of stroke;\n* Completed inpatient rehabilitation;\n* A level of ability that would allow them to participate safely (as determined by ESD team);\n* Cognitive ability to consent and take part;\n* Technological ability and resources to allow them to access MRPS platform;\n* A proficiency in the English Language.\n\nExclusion Criteria:\n\n* Involvement in other studies or rehabilitation programmes;\n* A level of disability that would prevent them from participating safely (as determined by ESD team);\n* Low level technological literacy or resources (e.g. Wi-Fi) which would prevent access to MRPS platform;\n* Have uncontrolled medical condition or another serious medication condition in addition to stroke;\n* Unable to understand or follow directions.",{"count":183,"type":22},14,[59],"The aim of this pilot trial is to examine and compare the safety and feasibility of enhanced Early Supported Discharge (ESD) through the Mechatronic Remote Physiotherapy System (MRPS) and traditional ESD after stroke.\n\nThe main questions this trial aims to answer are:\n\n* Is enhanced ESD via the MRPS safe, feasible and significantly different compared to traditional ESD when administered to patients after stroke?\n* Do patients interact with and are they satisfied with the MRPS?\n* Is enhanced ESD cost-effective compared to traditional ESD?\n* Are there any adverse effects of the MRPS and what are the areas for further improvement?\n\nParticipants in the experimental group will receive enhanced ESD through the MRPS.\n\nThe intervention will be given for approximately 6-8 weeks in total. Frequency will be determined by how often the participants' use the MRPS themselves. Frequency of use and level of completion of each session will be monitored. Enhanced ESD therapy sessions will be designed to reflect traditional ESD sessions.\n\nParticipants in the control group will receive traditional ESD. The intervention will be given for approximately 6-8 weeks in total with a frequency of 1-3 therapy visits per week (as per traditional ESD). Therapy sessions will be designed by therapists delivering the ESD service.",[187,27],"Stroke",[189,190,191,192,193],"Remote rehabilitation","Neurorehabilitation","Upper limb","Lower limb","Early Supported Discharge","NOT_YET_RECRUITING","2025-05-11",{"date":197,"type":41},"2025-05-14",{"date":199,"type":22},"2026-04-01",{"date":201,"type":22},"2027-12-01",{"name":203,"class":100},"Institute of Technology, Sligo",{"id":205,"slug":206,"hasResults":11,"nctId":207,"briefTitle":208,"officialTitle":208,"acronym":209,"eligibilityCriteria":210,"healthyVolunteers":16,"sex":17,"minAge":108,"maxAge":4,"enrollmentInfo":211,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":213,"conditions":214,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":225},"100532929","automatic-voice-analysis-for-dysphagia-screening-in-neurological-patients-100532929","NCT06219200","Automatic Voice Analysis for Dysphagia Screening in Neurological Patients","VOICED","Inclusion Criteria:\n\n* Patients with a diagnosis of stroke, Parkinson's disease, or amyotrophic lateral sclerosis, or healthy individuals.\n* Age higher than 18 years old.\n\nExclusion Criteria:\n\n* Cognitive impairment that do not allow participants to understand the requested vocal tasks.\n* Ear, nose,throat diseases and other disorders able to affect voice quality.",{"count":212,"type":22},400,"The proposed study suggests using automatic voice analysis and machine learning algorithms to develop a dysphagia screening tool for neurological patients. The research involves patients with Parkinson's disease, stroke, and amyotrophic lateral sclerosis, both with and without dysphagia, along with healthy individuals. Participants perform various vocal tasks during a single recording session. Voice signals are analysed and used as input for machine learning classification algorithms. The significance of this study is that oropharyngeal dysphagia, a condition involving swallowing difficulties in the transit of food or liquids from the mouth to the esophagus, generates malnutrition, dehydration, and pneumonia, significantly contributing to management costs and hospitalization durations. Currently, there is a lack of rapid and effective dysphagia screening methods for healthcare personnel, with only expensive invasive tests and clinical scales in use.",[215,27],"Deglutition Disorders","2025-02-19",{"date":218,"type":41},"2025-02-20",{"date":220,"type":41},"2023-10-11",{"date":222,"type":22},"2025-12",{"name":224,"class":100},"Istituti Clinici Scientifici Maugeri SpA",2,{"id":227,"slug":228,"hasResults":11,"nctId":229,"briefTitle":230,"officialTitle":231,"acronym":232,"eligibilityCriteria":233,"healthyVolunteers":16,"sex":17,"minAge":234,"maxAge":235,"enrollmentInfo":236,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":238,"conditions":239,"keywords":242,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":253,"locationsCount":47},"100537525","families-filming-infants-learning-movement-100537525","NCT06278961","Families Filming Infants Learning Movement","The Ontogeny of Fidgety Movements in Infants At High-Risk of Cerebral Palsy","FILM","Inclusion Criteria:\n\n* Infants born full-term with typical development, bithweight \\>2500g\n* Infants with a history of brochopulmonary dysplasia, defined as having a preterm birth (\\\u003C33 weeks gestational age) and requiring supplemental oxygen beyond 36 weeks gestational age\n* Infants with neonatal encephalopathy, who required hypothermic cooling treatment\n* Infants born \\\u003C36 weeks gestational age\n* Infants born in a multiple gestation pregnancy\n* Infants with a diagnosis of Trisomy 21\n* Infants born and diagnosed with SMA prenatally, via newborn screening assessment or prior to 10 weeks corrected age\n* Infants are less than 10 weeks corrected age at time of enrollment\n\nExclusion Criteria:\n\n* Children who are enrolled in DCFS custody\n* Parent or infant guardian does not have a smartphone","10 Weeks","20 Weeks",{"count":237,"type":22},350,"The study objective is to improve accuracy in the early detection of neurodevelopmental impairment, especially CP, by evaluating the timepoint (in weeks post term age) that the Prechtl GMA is most useful for prediction of neurodevelopmental impairment at two years of age in children with and without medical complexity. The study team plans to recruit 100 healthy, term-born infants and 250 infants at risk of developing CP for a total of 350 enrolled infants.",[240,90,241,27],"Infant Development","Motor Disorders",[243,244,245],"fidgety movements","general movement assessment","cerebral palsy","2025-02-11",{"date":248,"type":41},"2025-02-13",{"date":250,"type":41},"2021-01-28",{"date":252,"type":22},"2026-09-30",{"name":254,"class":100},"Ann & Robert H Lurie Children's Hospital of Chicago",{"id":256,"slug":257,"hasResults":11,"nctId":258,"briefTitle":259,"officialTitle":260,"acronym":4,"eligibilityCriteria":261,"healthyVolunteers":11,"sex":17,"minAge":262,"maxAge":263,"enrollmentInfo":264,"targetDuration":4,"studyType":57,"phases":266,"briefSummary":267,"conditions":268,"keywords":269,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":47},"100398384","transcutaneous-stimulation-for-neurological-populations-100398384","NCT04467437","Transcutaneous Stimulation for Neurological Populations","Transcutaneous Spinal Stimulation With Intensive Gait Training for Individuals With Neurologic Conditions","Inclusion Criteria:\n\n* have a neurologic condition\n* can walk 20 yards, with or without an assistive device\n* have stable medical condition\n* are capable of performing simple cued motor tasks and who can follow 2-3 step commands\n* have ability to attend up to 5 sessions per week physical therapy sessions and testing activities\n* have adequate social support to be able to participate in training and assessment sessions, up to 5 sessions per week, for the duration of up to 11 months within the study period.\n* who are volunteering to be involved in this study\n* can read and speak English\n\nExclusion Criteria:\n\n* have significant medical disease; including uncontrolled systemic hypertension with values above 170\u002F100 mmHg; cardiac or pulmonary disease; uncorrected coagulation abnormalities or need for therapeutic anticoagulation.\n* have cardiovascular or musculoskeletal disease or injury that would prevent full participation in physical therapy intervention\n* have a history of uncontrolled seizures\n* have unhealed fracture or other musculoskeletal impairment that might interfere with lower extremity rehabilitation or testing activities\n* are dependent on ventilation support\n* have implanted stimulator (e.g. epidural stimulator, vagus nerve stimulator, pacemaker, cochlear implant, etc) or drug delivery device (e.g. baclofen pump)\n* have history of orthopedic surgery in lower extremities or neurosurgery that may be a confounding factor for interpretation of the results (such as tendon transfer, tendon or muscle lengthening for spasticity management, injection therapies to lower extremity muscles, etc.) in last 12 months\n* have established osteoporosis and taking medication for osteoporosis treatment.\n* have rheumatic diseases (rheumatoid arthritis, systemic lupus erythematosus, etc.)\n* have active cancer","4 Years","70 Years",{"count":265,"type":22},20,[59],"The purpose of the study is to evaluate whether non-invasive stimulation over the spinal cord at the neck and\u002For lower back can improve walking function for people with neurologic conditions. Spinal stimulation has been used extensively for individuals with spinal cord injury, and has demonstrated improvements in function. This study will extend this work to other neurologic conditions, such as cerebral palsy and stroke, that also demonstrate similar impairments as spinal cord injury.\n\nThe primary aims of this study are to:\n\nAim 1: Evaluate impact of spinal stimulation on spasticity and locomotor function.\n\nAim 2: Investigate participant perceptions of spinal stimulation.\n\nThe investigators will be using a cross-over design study to compare intensive training only to intensive training combined with spinal stimulation. After an initial baseline period of up to 4 weeks (Phase I). Participants will have their first intervention phase of the study (Phase II). This will involve either intensive training only (Condition A) or intensive training combined with spinal stimulation (Condition B). This will be followed by a washout period with no intervention (Phase III) and then the second intervention phase (Phase IV). The second intervention phase will involve either Condition A or Condition B, whichever the participants did not received during Phase II. Phases II-IV will each last up to 8 weeks. After the intervention period is complete, the participant will be asked to come for follow-up visits up to 3 months after the intervention phases are completed (Phase V).",[27,90],[270,271],"Spinal Electrical Stimulation","Treadmill Training","2024-09-05",{"date":274,"type":41},"2024-09-19",{"date":276,"type":41},"2021-01-01",{"date":278,"type":22},"2027-12",{"name":280,"class":100},"University of Washington",{"id":282,"slug":283,"hasResults":11,"nctId":284,"briefTitle":285,"officialTitle":286,"acronym":4,"eligibilityCriteria":287,"healthyVolunteers":16,"sex":17,"minAge":108,"maxAge":4,"enrollmentInfo":288,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":290,"conditions":291,"keywords":294,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":47},"100447460","wearable-devices-and-biomarkers-project-healthiomics-100447460","NCT05106725","Wearable Devices and Biomarkers Project (Healthiomics)","Study of Clinical Biomarkers in Human Health and Disease (Healthiomics)","Inclusion Criteria:\n\n* Participant or participant's legally authorized representative has the ability to understand and the willingness to provide a signed and dated informed consent form.\n* Participant is ≥ 18 years of age.\n* Participant had\u002Fhas a scheduled appointment with oncology or neurosciences services at the participating medical and surgical facility.\n* Participant is characterized by at least one of the following criteria:\n\n  1. Has a neurological complication from any type of cancer, or is under evaluation for a possible cancer diagnosis or neurologic complication. Participant may be newly diagnosed, in relapse, or be free of disease at the time of recruitment. Participant without a confirmed cancer diagnosis is eligible.; OR\n  2. Has a neurological disorder, or is under evaluation for a possible diagnosis of a neurological disorder; OR\n  3. Does not meet the characteristic of either a. or b. above. This participant would be considered a \"healthy control\" for cancer and neurological disorders.\n\nExclusion Criteria:\n\n* Participant or participant's legally authorized representative is unable to provide informed consent.",{"count":289,"type":22},3500,"The purpose of this study is to collect clinical data, biological specimens (e.g., blood, tumor, cerebrospinal fluid, urine sample, etc.), and digital health data from patients with tumors, cancer and\u002For neurological disorders in order to perform research studies that could advance patient care. By collecting these specimens, the investigators plan to create and maintain a biorepository to make data and specimens available to collaborating investigators performing research to discover predictive biomarkers, patterns of care, and personalized treatments that could directly improve the care of our patients through focused proof-of-concept clinical trials.",[292,27,293],"Brain Cancer","Neurological Cancer",[295,296,297],"wearables","digital health","biospecimens","2024-08-19",{"date":300,"type":41},"2024-08-21",{"date":302,"type":41},"2021-10-11",{"date":304,"type":22},"2025-12-31",{"name":306,"class":100},"CureScience",{"id":308,"slug":309,"hasResults":11,"nctId":310,"briefTitle":311,"officialTitle":312,"acronym":4,"eligibilityCriteria":313,"healthyVolunteers":11,"sex":17,"minAge":108,"maxAge":4,"enrollmentInfo":314,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":316,"conditions":317,"keywords":318,"overallStatus":194,"whyStopped":4,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":322,"startDateStruct":324,"completionDateStruct":326,"leadSponsor":328,"locationsCount":4},"100555332","nutritional-risk-for-hospitalized-patients-with-neurology-disorders-in-china-100555332","NCT06510712","Nutritional Risk for Hospitalized Patients With Neurology Disorders in China","Nutritional Risk and Health Research for Hospitalized Patients With Neurology Disorders in China","Inclusion Criteria:\n\n1. Age ≥ 18 years;\n2. The primary diagnosis was neurological disorders;\n3. Written informed consent.\n\nExclusion Criteria:\n\n1. Life expectancy is \\\u003C 3 months;\n2. Researchers think other ineligible participant for the study.",{"count":315,"type":22},10000,"Neurology disorders are one of the major public health problems that seriously threaten human health. It often accompanied by various nutritional problems, which can aggravate the primary disease, lead to serious complications, prolong the hospitalization, lead to poor prognosis, and increase family and social economic burdens. According to the previous studies, the risk of malnutrition was approximately 58.5% of stroke patients, and 6% had moderate to severe malnutrition in China. Another study conducted in Beijing showed that the risk of malnutrition of elderly patients in the department of neurology was significantly higher than in other departments (28.5% vs. 26.4%). Strengthening nutritional supervision of patients with neurology disorders will benefit to improve patients' prognosis. Therefore, the aim of this study is to investigate the nutritional status of inpatients with neurology disorders in China, evaluate the impact of different nutritional status on patients' health outcomes, and establish a high-quality, standardized nutrition and health cohort database for neurology disorders.",[27],[319,320],"nutrition","the risk of malnutrition","2024-07-14",{"date":323,"type":41},"2024-07-19",{"date":325,"type":22},"2024-09-01",{"date":327,"type":22},"2026-06-30",{"name":329,"class":100},"Xuanwu Hospital, Beijing"]